Infective myocarditis
Conditions
Interventions
28day~ < 1 year old:0.5 g IV BID
1~ < 6 years old :1.0 g IV BID
6~ < 18 years old:2.0 g IV BID
Sponsors
Beijing Children's Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients (under 18 years old) with infective myocarditis; 2. Patients diagnosed as infective myocarditis (according with 2 of diagnostic criteria): (1) cardiac dysfunction, cardiac shock or cardio-cerebral syndrome; (2) cardiac dilatation (according to X-ray or echocardiography examination); (3) ECG changes: ST-T changes of 2 or more major leads (I, II, aVF, V5) dominated by R wave last more than 4 days accompanied by dynamic changes, sinoatrial block, Ventricular block, completely right or left bundle branch block, into the law, polymorphism, multi-source, paired or parallel premature beats, non-atrioventricular node and atrioventricular reentrant-induced atopic tachycardia, low Voltage (except for newborns) and abnormal Q waves; (4) elevated CK-MB or positive result for cardiac troponin (cTnI or cTnT); 3. Patients with acute stage of the myocarditis clinical staging; 4. All the subjects or their guardians must sign the consent form before entering the trial.
Exclusion criteria
Exclusion criteria: 1. Patients with fulminant myocarditis (diagnostic criteria refer to September 1999 Kunming National Pediatric myocarditis, cardiomyopathy conference developed diagnostic criteria of children with viral myocarditis (drafted version), which is that the disease is extremely rapid developed, in a few hours or 1-2 Days that occurred acute cardiac insufficiency or cardiogenic shock, excluding other causes of secondary changes, diagnosis of fulminant myocarditis); 2. Patients with myocardial damage caused by rheumatic myocarditis, toxic myocarditis, congenital heart disease, connective tissue disease or metabolic diseases, hyperthyroidism, primary cardiomyopathy, primary endocardial fibroelastosis, congenital atrioventricular block, cardiac autonomic dysfunction, ß receptor hyperactivity or drug-induced ECG changes; 3. Patients currently with other serious and unstable physical illnesses including cardiovascular, liver, kidney, gastrointestinal, respiratory, endocrine, neurological, immune system, blood system, epilepsy, and other diseases that may interfere with clinical trial results or that increase patients' risks; 4. Patients with myocardial injury caused by other reasons; 5. Patients with heart disease history or complications; 6. Patients who are allergic to creatine phosphate; 7. Patients with allergic constitution, or who was allergy to any food or require for special diet, or allergy to the routine medication and associated drug in this study; 8. Patients who participated in any other clinical trial within 3 months before baseline; 9. Patients with other serious infectious diseases during screening period; 10. Subjects who may not be able to complete the study for other reasons; 11. Patients who has uncured dehydration, acidosis, hypotension, renal disorder, or are using drugs with nephrotoxicity; 12. Patients with other conditions that are not suitable for enrollment according to the researcher's standard.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ECG;Myocardial enzymes;Echocardiography; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical symptoms and signs; | — |
Countries
China
Contacts
Public ContactYue Yuan, Xiaoling Wang
Beijing Children's Hospital, Capital Medical University
Outcome results
None listed